Famotidine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Famotidine: From Peptic Ulcer Disease to Duodenogastric Reflux
One-Sentence Summary
Famotidine is a potent, highly selective histamine H2-receptor antagonist widely recognized for suppressing gastric acid secretion and treating peptic ulcer disease across global markets. The TxGNN model predicts it may also be effective for Duodenogastric Reflux, with 0 clinical trials and 2 publications currently supporting this specific direction. It is worth noting that broader acid-related conditions within the same evidence pack—such as peptic ulcer disease (rank 8) and active peptic ulcer disease (rank 3)—carry substantially stronger L1–L2 evidence with up to 14 clinical trials and 20 publications, suggesting famotidine’s repurposing value lies predominantly in established acid-peptic disease management rather than novel mechanisms.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No Philippines FDA registration on record |
| Predicted New Indication | Duodenogastric Reflux |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L3 |
| Philippines Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the DrugBank query included in this evidence pack. Based on established pharmacological knowledge, Famotidine is a highly selective competitive antagonist of histamine H2 receptors on gastric parietal cells. By blocking H2-mediated signaling, it suppresses both basal and histamine-stimulated gastric acid secretion by approximately 65–70%, with the most pronounced effect on nocturnal acid output. A single 40 mg bedtime dose maintains intragastric pH above 3.5 for roughly 10–12 hours—an acid-suppressing profile that underpins its widespread clinical use across multiple acid-peptic conditions.
Duodenogastric reflux (DGR) involves retrograde flow of duodenal contents—primarily bile acids, lysolecithin, and pancreatic enzymes—from the duodenum into the stomach. While bile acids are themselves non-acidic, their cytotoxic effect on gastric mucosa is significantly amplified in an acidic environment, where they convert to more membrane-permeable forms capable of disrupting the mucosal barrier. By elevating intragastric pH, Famotidine could theoretically reduce bile acid toxicity and limit mucosal damage caused by mixed (acid + bile) refluxate. This is particularly relevant in critically ill patients experiencing duodeno-gastro-esophageal reflux (DGER), where famotidine has been evaluated (PMID 12532466).
However, the mechanistic overlap is partial rather than complete. H2-receptor antagonists do not address the root cause of DGR—impaired pyloric sphincter function and disordered gastroduodenal motility—nor do they neutralize bile acids directly. Famotidine’s utility is therefore plausible for acid-amplified DGR but insufficient for pure bile reflux, which requires motility-modifying or bile-sequestering strategies.
Clinical Trial Evidence
Currently no related clinical trials registered for duodenogastric reflux.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12532466 | 2003 | Clinical Observational Study | World Journal of Gastroenterology | Investigated famotidine’s effect on GER and DGER in critically ill patients; explored possible mechanisms and identified factors associated with reflux severity |
| 16259441 | 2004 | Clinical Study | Experimental & Clinical Gastroenterology | Evaluated famotidine 20 mg BID for early-stage gastroduodenal reflux disease (grades 0–1 on the modified Savary-Miller scale) via clinical and endoscopic assessment |
Philippines Market Information
Famotidine currently has no products registered with the FDA Philippines. There are no valid authorization records on file.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Research Question
Rationale: Evidence specifically supporting famotidine for duodenogastric reflux is limited to 2 observational publications with no registered clinical trials. While acid suppression provides a partial mechanistic rationale, the primary pathophysiology of duodenogastric reflux—bile acid backflow and motility dysfunction—falls outside famotidine’s pharmacological scope.
To proceed, the following is needed:
- Formal mechanism of action data (H2 receptor binding profile, pharmacodynamics) from DrugBank or prescribing information
- Philippines FDA package insert or equivalent regulatory safety document (warnings, contraindications, drug interactions)
- Prospective controlled studies enrolling DGR patients with duodenogastric reflux as the primary efficacy endpoint
- Sub-group analysis distinguishing acid-amplified DGR (where famotidine may contribute) from pure bile reflux (where famotidine is insufficient)
- Head-to-head comparison with proton pump inhibitors, which achieve more sustained acid suppression and are considered the current standard for acid-peptic conditions in the Philippines market
- Philippines registration pathway assessment, given the drug is currently not marketed locally
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.